Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Education And Data Will Be Key To Byooviz Uptake

Real-World Evidence Is Expected To Help Build Confidence In US Lucentis Biosimilar

Executive Summary

Education for healthcare professionals and real-world evidence will be important factors in building trust in Byooviz, Samsung Bioepis and Biogen have told Generics Bulletin, acknowledging it will “take some time” for ophthalmologists to grow more comfortable prescribing biosimilars.

You may also be interested in...



Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch

CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.

Competition Intensifies As Access Increases For US Biosimilars

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.

Supply Security And Competitive Pricing Will Support Byooviz Launch In US

In the first part of an exclusive two-part interview, Samsung Bioepis’ development division leader Kyung-Ah Kim and Biogen’s global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel